Medtronic Receives CE (Conformité Européenne) Mark Approval for the Percept™ PC Neurostimulator DBS System with BrainSense™ Technology.
This new system can sense and record brain signals while delivering therapy to patients with neurologic disorders, such as Dystonia. This enables physicians to deliver more data-driven, personal neurostimulation treatment. The neurostimulator has been approved in the EU for treatment of symptoms associated with essential tremor, primary dystonia, epilepsy, parkinsons disease (PD) and obsessive-compulsive disorder (OCD). It is also currently under review by the U.S. Food and Drug Administration.
The Percept PC neurostimulatar will be available in Western Europe beginning January 15th and will launch in additional regions based on local regulations.
For more information you can read the press release and go to the Medtronic website:
- Medtronic Receives CE Mark Approval for the Percept™ PC Neurostimulator DBS System with BrainSense™ Technology – press release
- Medtronic global website
Disclaimer:
Dystonia Europe is sharing this information from the press release from Medtronic, and this article should not be taken to be the views, or recommendation from Dystonia Europe of any particular treatments, therapies or products.
